Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT2000 for ocular pain in moderate to severe dry eye disease
ACTRN12626000137392Phase 2Not yet recruiting
- Sponsor
- Channel Therapeutics
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of CT2000 in dry eye syndrome (DED) (8 arms), sponsored by Channel Therapeutics. Primary endpoints: Maximum tolerated dose of CT2000 and Safety and tolerability composite. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
CT2000
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on ACTRN12626000137392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626000137392.